@EndoCancer

Publishing translational & clinical investigations of human health & disease focusing on #endocrine neoplasias & hormone-dependent #cancers. Owned by @soc_endo.

erc.bioscientifica.com/
Joined August 2014
  • Tweets2.1K
  • Following1.4K
  • Followers3.3K
1KMedia
📢 Endocrine-Related Cancer is pausing activity on X. To stay up to date with journal news and research, follow us on: 🌐LinkedIn: linkedin.com/company/endocri… 🦋Bluesky: bsky.app/profile/endocancer.… Thanks for staying connected and being part of our community!
1
245
Wondering where we've been? We've been sharing the latest research, special collections, editorial opportunities and journal updates on LinkedIn. To keep up with the research & discussions shaping endocrine oncology, connect with us: 🔗 linkedin.com/company/endocri…

Endocrine-Related Cancer | LinkedIn

Endocrine-Related Cancer | 304 followers on LinkedIn. Flagship journal of Society for Endocrinology, publishing research on endocrine neoplasias & hormone-dependent cancers. | Endocrine-Related...

linkedin.com
75
Endocrine-Related Cancer retweeted
Karagiannis Lab@GeorgiosKaragi5May 19
erc.bioscientifica.com/view/… Really happy for our new publication in @EndoCancer describing an interplay between breast tumor cells and cancer-associated adipocytes. Fantastic work from the team, the first author Dimitris Argyris and our long-time collaborator @PanagiotaFilip3!

Proteomic signatures of adipocyte recruitment in breast cancer

The tumor microenvironment (TME) is increasingly recognized as a dynamic regulator of breast cancer progression, with adipocytes functioning as active contributors rather than passive bystanders....

journals.bioscientifica.com
4
1
11
1,051
Endocrine-Related Cancer retweeted
Udhayvir Grewal
@UGrewalMDJun 8
Finally out!!- A critical appraisal of literature and several practical insights from surgeon extraordinaire @SethConcorsMD and team on the role of primary tumor resection for patients with small bowel neuroendocrine tumors in the setting of metastatic disease @EndoCancer. @WinshipAtEmory @TheGutOncLab erc.bioscientifica.com/view/… On a personal note- I do think there is a role for PTR among patients with a symptomatic primary (caveat: symptoms can be very subtle or non-specific and therefore challenging to identify). The role of PTR remains less well-defined in asymptomatic primary tumors, especially among those with relatively indolent disease.
7
17
1,177
Endocrine-Related Cancer retweeted
Bence Kövér@kover_benceJul 3
Very proud to have contributed to this review paper published in @EndoCancer led by James Kaufman-Cook and supervised by Cynthia Andoniadou. doi.org/10.1530/ERC-26-0171

The role of stem cells in pituitary tumour formation

Pituitary tumours are intracranial neoplasms that pose significant clinical challenges due to their potential for recurrence, therapeutic resistance and resultant endocrine dysfunction and mass...

journals.bioscientifica.com
1
1
3
79
Endocrine-Related Cancer retweeted
Udhayvir Grewal
@UGrewalMDJul 13
Happy to share our invited review on "Grade progression and high-grade transformation in Neuroendocrine Neoplasms" just out in @EndoCancer. 🔗 shorturl.at/UpxlF Forever grateful to @IHC_guy for his mentorship on this and several other projects (crazy that I even know you and get to work with you). We hope that this will be a helpful guide for colleagues while dealing with this clinical challenge that I find to be incredibly hard to navigate. Thank you @NANETS1 for the nomination and co-authors @ChandrikhaC @PoHienEar @RaulSGonzalezMD @SethConcorsMD for your contribution to this work.
1
13
34
1,817
Endocrine-Related Cancer retweeted
Julie Hallet
@HalletJulieJul 25
🦓Well-differentiated NETs can change Review on NEN transformation by @UGrewalMD 🔬Rising Ki-67 + TP53 (±RB1) →NEC-like behavior on a NET backbone 🔑Old info can mislead decisions 🎯Implication: re-biopsy the progressing lesion, re-profile, re-image doi.org/10.1530/ERC-26-0017
🤖 Made with AI
2
10
25
1,653
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19. The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other. Register now: bit.ly/4nQ9goU #NETresearch
Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.

ALT Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.

2
162
Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more. Explore the collection: erc.bioscientifica.com/page/…
2
4
461
🔬 Discovery of a novel sodium iodide symporter (NIS) regulatory pathway in breast cancer cells. @Vikki_L_Poole et al. opens new therapeutic avenues in #BreastCancer by mapping NIS regulation & pinpointing targets to boost RAI-avidity. Read #OpenAccess: doi.org/10.1530/ERC-24-0312
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer in Endocrine-Related Cancer. By Vikki L Poole et al. Published by Bioscientifica. Society for Endocrinology. Figure 1. Phosphorylated PBF represses RAIU in breast cancer cells. (A) Left – schematic of the interaction between NIS and PBF proteins tagged at the C-terminus with the NanoLuc luciferase subunits LgBiT and SmBiT, respectively. In close proximity, LgBiT and SmBiT form a functional enzyme that uses the substrate furimazine to produce a high-intensity, luminescent signal. Created using Alphafold (59, 60) and BioRender. Right – NanoBiT analysis of NIS:PBF interaction in MCF-7 cells, with bar graph showing results at 20 min post-addition of Nano-Glo live cell assay substrate. (B) Co-immunoprecipitation assay showing PBF-HA and NIS-MYC interaction in MCF-7 breast cancer cells. (C) Schematic of PBF highlighting the overlapping phosphorylation site...Endocrine-Related Cancer 32, 8; 10.1530/ERC-24-0312

ALT Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer in Endocrine-Related Cancer. By Vikki L Poole et al. Published by Bioscientifica. Society for Endocrinology. Figure 1. Phosphorylated PBF represses RAIU in breast cancer cells. (A) Left – schematic of the interaction between NIS and PBF proteins tagged at the C-terminus with the NanoLuc luciferase subunits LgBiT and SmBiT, respectively. In close proximity, LgBiT and SmBiT form a functional enzyme that uses the substrate furimazine to produce a high-intensity, luminescent signal. Created using Alphafold (59, 60) and BioRender. Right – NanoBiT analysis of NIS:PBF interaction in MCF-7 cells, with bar graph showing results at 20 min post-addition of Nano-Glo live cell assay substrate. (B) Co-immunoprecipitation assay showing PBF-HA and NIS-MYC interaction in MCF-7 breast cancer cells. (C) Schematic of PBF highlighting the overlapping phosphorylation site...Endocrine-Related Cancer 32, 8; 10.1530/ERC-24-0312

95
New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎 🎯Could HO-1 be a therapeutic target? Subscribers can read the research: doi.org/10.1530/ERC-25-0177
Heme-oxygenase-1: a key player in thyroid carcinoma development in Endocrine-Related Cancer. By Exequiel Gonzalo Alonso et al. Graphical Abstract. Published by bioscientifica. Society for Endocrinology.

ALT Heme-oxygenase-1: a key player in thyroid carcinoma development in Endocrine-Related Cancer. By Exequiel Gonzalo Alonso et al. Graphical Abstract. Published by bioscientifica. Society for Endocrinology.

1
107
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours! We welcome basic, translational & clinical studies that advance understanding & showcase innovations. 📩Submit your proposal to: [email protected] 🌐More info: bit.ly/4mUXslc
Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD

ALT Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD

1
2
174
🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade. A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance. 🔗doi.org/10.1530/ERC-24-0291
1
152
🌱Endocrine-Related Cancer is officially on LinkedIn! Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal: 🌐linkedin.com/company/endocri…
Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.

ALT Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.

1
3
182
✨Systems biology approaches are reshaping our understanding of cancer. Latest review by Michael V Orman et al. (@CUPharmacology) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer. #OpenAccess - doi.org/10.1530/ERC-25-0067
Endocrine-Related Cancer. Themed Collection: Systems Biology Approaches in Hormone Dependent Cancer Research. New Review: Systems biology successes and areas for opportunity in prostate cancer in Endocrine-Related Cancer. By Michael V Orman et al.

ALT Endocrine-Related Cancer. Themed Collection: Systems Biology Approaches in Hormone Dependent Cancer Research. New Review: Systems biology successes and areas for opportunity in prostate cancer in Endocrine-Related Cancer. By Michael V Orman et al.

140
🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at @Griffith_Health, has joined Endocrine-Related Cancer's editorial board as an Associate Editor. Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326
Endocrine-Related Cancer. New Associate Editor. Professor Alfred Lam. Professor of Pathology, Griffith University, Australia. Latest Research: Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid. By Steven Weller, Cordia Chu, and Alfred King-yin Lam

ALT Endocrine-Related Cancer. New Associate Editor. Professor Alfred Lam. Professor of Pathology, Griffith University, Australia. Latest Research: Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid. By Steven Weller, Cordia Chu, and Alfred King-yin Lam

120
Sponsored by @CureNETs, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research. Learn more: mierf.org/to-apply/ #neuroendocrinecancer #earlycareerresearcher
The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.

ALT The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.

1
1
273
🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy? Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC. 🔗Explore the results: doi.org/10.1530/ERC-25-0031
DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer in Endocrine-Related Cancer. By Shu-Fu Lin et al. Society for Endocrinology, Published by bioscientifica.

ALT DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer in Endocrine-Related Cancer. By Shu-Fu Lin et al. Society for Endocrinology, Published by bioscientifica.

1
106
How do treatments for neuroendocrine neoplasms impact quality of life? A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on QoL in NEN survivors. 📖 Read more: doi.org/10.1530/ERC-24-0303
New Review in Emerging Leaders 2025 Special Collection. Impact of treatment on quality of life in neuroendocrine neoplasm survivors in Endocrine-Related Cancer. By Roberta Modica et al. Endocrine-Related Cancer.

ALT New Review in Emerging Leaders 2025 Special Collection. Impact of treatment on quality of life in neuroendocrine neoplasm survivors in Endocrine-Related Cancer. By Roberta Modica et al. Endocrine-Related Cancer.

2
160
✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer! Dr. Pacak's term begins on 1st January 2026. We are excited for this next chapter, driven by his expertise and vision🚀
Endocrine-Related Cancer. Incoming Editor-in-Chief, Dr Karel Pacak. "It is a great honor to assume the role of Editor-in-Chief of Endocrine-Related Cancer, a journal fully committed to raising awareness of endocrine cancers among healthcare providers by supporting excellence in basic and clinical research, high-quality studies, and evidence-based guidelines." Published by Bioscientifica. Society for Endocrinology.

ALT Endocrine-Related Cancer. Incoming Editor-in-Chief, Dr Karel Pacak. "It is a great honor to assume the role of Editor-in-Chief of Endocrine-Related Cancer, a journal fully committed to raising awareness of endocrine cancers among healthcare providers by supporting excellence in basic and clinical research, high-quality studies, and evidence-based guidelines." Published by Bioscientifica. Society for Endocrinology.

2
113

No more items